LI
TGTX icon

Leap Investments’s TG Therapeutics TGTX Stock Holding History

Leap Investments’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		$362K Buy
18,600
+2,400
+15% +$38.7K 0.24% 159
2020
Q1 		$159K Sell
16,200
-43,844
-73% -$554K 0.23% 193
2019
Q4 		$666K Buy
+60,044
New +$457K 0.31% 104

Other funds holding TGTX

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Leap Investments's TGTX Position: Q2 2020 in Review

Leap Investments increased its TG Therapeutics (TGTX) stake by 15% in Q2 2020, buying an estimated $38.7K and bringing the position to 18,600 shares worth $362K. The position accounts for 0.24% of the portfolio, ranked #159.

Leap Investments first reported a position in TGTX in Q4 2019 and has held it in 3 quarters since. The position peaked at $666K in Q4 2019. 175 funds tracked by Wall St. Rank hold TGTX as of Q2 2020.

  • Leap Investments held 18,600 shares of TG Therapeutics worth $362K as of Q2 2020.
  • Leap Investments bought 2,400 TG Therapeutics shares in Q2 2020, an estimated $38.7K.
  • TG Therapeutics made up 0.24% of Leap Investments's portfolio in Q2 2020, its #159 holding.
  • Leap Investments first reported a position in TG Therapeutics in Q4 2019 and has held it in 3 quarters since.
  • Leap Investments's TG Therapeutics position peaked at $666K in Q4 2019.
  • 175 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.